Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to know and Medicare coverage ...

Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.

The Trump administration’s new TrumpRx deal with Eli Lilly and Novo Nordisk will slash GLP-1 drug prices, including Ozempic, ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive ...

Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices to patients in the U.S ...

The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.